Most cancer drugs are designed to interfere with one or more events in cell proliferation or
survival. As healthy cells may also need to proliferate and avoid apoptosis, anticancer …

Antibody-drug conjugates (ADCs) are cancer therapeutic agents comprised of an antibody,
a linker and a small-molecule payload. ADCs use the specificity of the antibody to target the …

Highlights•Antibody–drug conjugates represent an exciting new class of cancer
therapeutics.•ADCs comprise monoclonal antibodies that selectively deliver potent cytotoxic …

Abstract The design of Antibody Drug Conjugates (ADCs) as efficient targeting agents for
tumor cell is still in its infancy for clinical applications. This approach incorporates the …

In the past two decades, extensive efforts have been made to develop agents targeting
prostate-specific membrane antigen (PSMA) for prostate cancer imaging and therapy. To …

The marine habitat has produced a significant number of very potent marine-derived agents
that have the potential to inhibit the growth of human tumor cells in vitro and, in a number of …

Antibody-drug conjugates (ADCs) are emerging as effective tools in cancer therapy,
combining the antibody's exquisite specificity for the target antigen-expressing cancer cell …

Simple Summary Currently, there is no treatment that can cure patients with late stage
metastatic prostate cancer. Prostate-specific membrane antigen is a type of protein …

Prostate cancer is the most commonly diagnosed malignancy in men and the second
leading cause of cancer-related deaths in Western civilization. Although localized prostate …

The prostate-specific membrane antigen (PSMA) is a molecular target whose use has
resulted in some of the most productive work toward imaging and treating prostate cancer …